Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02326844
Title BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland 20892 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field